New insight into early events in type 1 diabetes: Role for islet stem cell exosomes

Diabetes

Volumn 63, Issue 3, 2014, Pages 835-837

  Lukic, Miodrag L ^a   Pejnovic, Nada ^a,b   Lukic, Ana ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

^b University of Kragujevac Medical Faculty   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; AUTOIMMUNITY; EXOSOMES; ISLETS OF LANGERHANS; MESENCHYMAL STROMAL CELLS;

EID: 84894436233     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1786     Document Type: Note

References (17)

1. Lernmark A. Depleting T cells in newly diagnosed autoimmune (type 1) diabetes-are we getting anywhere? Diabetes 2013;62:3669-3670
2. Calderon B, Carrero JA, Unanue ER. The central role of antigen presentation in islets of Langerhans in autoimmune diabetes. Curr Opin Immunol 2014;26:32-40
3. Mensah-Brown EP, Shahin A, Al-Shamisi M, Wei X, Lukic ML. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur J Immunol 2006;36:216-223
4. Mensah-Brown EP, Shahin A, Al-Shamsi M, Lukic ML. New members of the interleukin-12 family of cytokines: IL-23 and IL-27 modulate autoimmune diabetes. Ann N Y Acad Sci 2006;1079:157-160
5. Guerder S, Joncker N, Mahiddine K, Serre L. Dendritic cells in tolerance and autoimmune diabetes. Curr Opin Immunol 2013;25:1-6
6. Tarbell KV, Petit L, Zuo X, et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007;204:191-201
7. Johnson MC, Garland AL, Nicolson SC, et al. b-Cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice. Diabetes 2013;62:3775-3784
8. Bashratyan R, Sheng H, Regn D, Rahman MJ, Dai YD. Insulinoma-released exosomes activate autoreactive marginal zone-like B cells that expand endogenously in prediabetic NOD mice. Eur J Immunol 2013;43:2588-2597
9. Rahman MJ, Regn D, Bashratyan R, Dai YD. Exosomes released by isletderived mesenchymal stem cells trigger autoimmune responses in NOD mice. Diabetes 2014;63:1008-1020
10. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008;57:1759-1767
11. Sheng H, Hassanali S, Nugent C, et al. Insulinoma-released exosomes or microparticles are immunostimulatory and can activate autoreactive T cells spontaneously developed in nonobese diabetic mice. J Immunol 2011;187: 1591-1600
12. Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev 2011;32:725-754
13. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 2011;29:5-10
14. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010;43:255-263
15. Madec AM, Mallone R, Afonso G, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52:1391-1399
16. Kim SH, Lechman ER, Bianco N, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 2005;174:6440-6448
17. Xie Y, Zhang H, Li W, et al. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. J Immunol 2010;185:5268-5278